149 related articles for article (PubMed ID: 36617366)
1. Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling.
Jaber MM; Brundage RC
J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):123-132. PubMed ID: 36617366
[TBL] [Abstract][Full Text] [Related]
2. Model-Based Residual Post-Processing for Residual Model Identification.
Ibrahim MMA; Nordgren R; Kjellsson MC; Karlsson MO
AAPS J; 2018 Jul; 20(5):81. PubMed ID: 29968184
[TBL] [Abstract][Full Text] [Related]
3. [Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters].
Ling J; Qian LX; Ding JJ; Jiao Z
Yao Xue Xue Bao; 2014 May; 49(5):686-94. PubMed ID: 25151742
[TBL] [Abstract][Full Text] [Related]
4. A reduction in between subject variability is not mandatory for selecting a new covariate.
Lagishetty CV; Vajjah P; Duffull SB
J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):383-92. PubMed ID: 22767340
[TBL] [Abstract][Full Text] [Related]
5. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
Fabre MA; Fuseau E; Ficheux H
J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
[TBL] [Abstract][Full Text] [Related]
6. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
Mu S; Ludden TM
J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
[TBL] [Abstract][Full Text] [Related]
7. Variability Attribution for Automated Model Building.
Ibrahim MMA; Nordgren R; Kjellsson MC; Karlsson MO
AAPS J; 2019 Mar; 21(3):37. PubMed ID: 30850918
[TBL] [Abstract][Full Text] [Related]
8. Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children's oncology group.
Edwards AY; Skolnik JM; Dombrowsky E; Patel D; Barrett JS
Cancer Chemother Pharmacol; 2012 Jul; 70(1):83-94. PubMed ID: 22623208
[TBL] [Abstract][Full Text] [Related]
9. Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients.
Guo T; Abdulla A; Koch BCP; van Hasselt JGC; Endeman H; Schouten JA; Elbers PWG; Brüggemann RJM; van Hest RM;
Clin Pharmacokinet; 2022 Jun; 61(6):869-879. PubMed ID: 35262847
[TBL] [Abstract][Full Text] [Related]
10. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data.
Sun H; Ette EI; Ludden TM
J Pharmacokinet Biopharm; 1996 Dec; 24(6):637-50. PubMed ID: 9300354
[TBL] [Abstract][Full Text] [Related]
11. Comparison of non-compartmental and mixed effect modelling methods for establishing bioequivalence for the case of two compartment kinetics and censored concentrations.
Hughes JH; Upton RN; Foster DJR
J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):233-244. PubMed ID: 28194623
[TBL] [Abstract][Full Text] [Related]
12. Impact of Inaccurate Documentation of Sampling and Infusion Time in Model-Informed Precision Dosing.
Alihodzic D; Broeker A; Baehr M; Kluge S; Langebrake C; Wicha SG
Front Pharmacol; 2020; 11():172. PubMed ID: 32194411
[TBL] [Abstract][Full Text] [Related]
13. Balanced designs in longitudinal population pharmacokinetic studies.
Ette EI; Sun H; Ludden TM
J Clin Pharmacol; 1998 May; 38(5):417-23. PubMed ID: 9602953
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
15. Estimation of pharmacokinetic parameters by orthogonal regression: comparison of four algorithms.
Tod M; Aouimer A; Petitjean O
Comput Methods Programs Biomed; 2002 Jan; 67(1):13-26. PubMed ID: 11750944
[TBL] [Abstract][Full Text] [Related]
16. Three new residual error models for population PK/PD analyses.
Karlsson MO; Beal SL; Sheiner LB
J Pharmacokinet Biopharm; 1995 Dec; 23(6):651-72. PubMed ID: 8733951
[TBL] [Abstract][Full Text] [Related]
17. Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients.
Piotrovsky VK; Huang ML; Van Peer A; Langenaecken C
Cancer Chemother Pharmacol; 1998; 42(3):221-8. PubMed ID: 9685057
[TBL] [Abstract][Full Text] [Related]
18. Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models.
Baverel PG; Savic RM; Karlsson MO
J Pharmacokinet Pharmacodyn; 2011 Feb; 38(1):63-82. PubMed ID: 21076858
[TBL] [Abstract][Full Text] [Related]
19. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.
Marathe A; Van Wart S; Mager DE
J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):223-35. PubMed ID: 21165681
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
